This study produced 20 research recommendations on novel psychoactive substance use, for researchers and research commissioners to use in developing the public health evidence-base (NIHR)
Archives for July 2017
Bibliography: All Publications
Hepatitis C in England and the UK
Latest hepatitis C virus (HCV) reports, slide sets and infographics for England and the UK (Public Health England)
EU Action Plan on Drugs 2017-2020
The Plan sets out the Actions that will be implemented to achieve the objectives of the Strategy (EUR-Lex)
Drug misuse: findings from the 2016 to 2017 CSEW
Examines the extent and trends in illicit drug use among a sample of 16 to 59 year old residents in households in England and Wales (Home Office)
Better care for people with co-occurring mental health and alcohol/drug use conditions (PDF)
A guide for commissioners and service providers (Public Health England)
More Australians dying of accidental overdose of pharmaceutical opioids
The report analyses cause of death data from the Australian Bureau of Statistics and found that in 2013, the last year for which finalised data is available, just under 600 (597) Australians between the ages of 15 and 54 died from accidental overdose of opioids with the majority 70 per cent being due to opioids other than heroin, including strong prescription painkillers (NDARC)
EMCDDA–Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA
This report presents the key activities performed by the EMCDDA and Europol in 2016 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, including new psychoactive substances notified in 2016 (EMCDDA)
Financial case for action on liver disease (PDF)
Escalating costs of alcohol misuse, obesity and viral hepatitis (Foundation for Liver Research)
Australian National Drug Strategy 2017-2026
For the first time, Australia has a long-term framework for reducing and preventing the harms associated with alcohol and other drugs through the agreement of a ten-year National Drug Strategy. This is a national strategic framework built on the principles of partnerships, coordination and collaboration, national direction and jurisdictional implementation, and evidence-informed response (Australian Government)
Crime in England and Wales: year ending March 2017
Includes a section o drugs (Office of National Statistics)
Canada’s Drug Futures Forum (PDF)
Summary of Proceedings and Final Recommendations (CDFF-FADE)
2017 Drug Strategy (PDF)
This Strategy sets out clear expectations for action from a wide range of partners, including those in education, health, safeguarding, criminal justice, housing and employment (HM Government, UK)
Drug misuse and dependence: UK guidelines on clinical management
Often called the Orange Book, this is guidance for clinicians treating people with drug problems (DoH, UK)
EMCDDA Budget 2017
The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre’s Director to the Management Board, which may modify the draft before adopting it and submitting it to the European Commission. The Commission, in turn, makes its recommendations (which may again alter the draft) and presents the result to the European Council and Parliament
Drug-related intimidation – The Irish situation and international responses: an evidence review (PDF)
This report presents the findings of an evidence review on drug-related intimidation (DRI) requested by the Department of Health on behalf of the Local and Regional Drugs and Alcohol Task Forces (HRB)
Reducing Harm, Supporting Recovery 2017 – 2025
Ireland’s “Reducing Harm, Supporting Recovery” strategy sets out the Government’s response to addressing the harm caused by substance misuse in our society over the next eight years. It identifies a set of key actions to be delivered between 2017 and 2020, and provides an opportunity for the development of further actions from 2021 to 2024 to address needs that may emerge later on in the lifetime of the strategy (DoH, Ireland)
The drugs situation in Ireland: an overview of trends from 2005 to 2015 (PDF)
This overview analyses ten years of data up to the most recent available with respect to the five European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) key indicators (prevalence of drug use, high risk drug use, treatment demand, drug-related deaths and mortality and drug-related infectious diseases) as well as drug-related crime and supply (Centre for Public Health at Liverpool John Moores University)
2017 Drug Strategy (PDF)
This Strategy sets out clear expectations for action from a wide range of partners, including those in education, health, safeguarding, criminal justice, housing and employment (Home Office)
EMCDDA–Europol Joint Report on a new psychoactive substance: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-carboxamide (furanylfentanyl)
The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 23 January 2017. Download
EMCDDA assessment of drug-induced death data and contextual information in selected countries
This report examines the triggers and dynamics of drug-related death in the seven EMCDDA Member States with the highest drug-related death (DRD) rates per population